Barbara Santevecchi

Barbara Santevecchi, Pharm.D., BCPS, BCIDP

Clinical Assistant Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (352) 594-5892
Business Email: bsantevecchi@ufl.edu

About Barbara Santevecchi

Barbara Santevecchi joined the College of Pharmacy as a Clinical Assistant Professor in the Department of Pharmacotherapy and Translational Research in August 2019. She serves as an Infectious Diseases Clinical Specialist and member of the Antimicrobial Management Program at UF Health Shands Hospital. She received her Doctor of Pharmacy degree from Wingate University School of Pharmacy in Wingate, North Carolina in 2015. Following graduation, she completed PGY1 Pharmacy Practice and PGY2 Infectious Diseases pharmacy residencies at the Medical University of South Carolina in Charleston, South Carolina. After completing residency training, she worked as an Infectious Diseases Clinical Pharmacist at Atrium Health in Charlotte, North Carolina. Barbara holds dual board certification in pharmacotherapy and infectious diseases. Her research interests include HIV/AIDS, microbiology, rapid diagnostics, novel agents for multidrug resistant infections, and antimicrobial stewardship. Barbara has published research in several peer-reviewed journals and has delivered presentations on her research at national meetings.

Accomplishments

Member
2016-Current · Infectious Diseases Society of America
Member
2013-Current · American College of Clinical Pharmacy

Teaching Profile

Courses Taught
2019-2022
PHA5788C Patient Care 6
2020-2023
PHA5782C Patient Care 2: Introduction to Infectious Disease and Oncology
2020
PHA5755 Micro, Immun, Virol
2019
PHA5163L Prac Skills Lab III
2021-2022
PHA5784C Pt Care 4: GI and Renal
2021-2022
PHA5876C Pt Care 8 Complex Pts

Board Certifications

  • Board Certified Infectious Diseases Pharmacist
    Board of Pharmacy Specialties
  • Board Certified Pharmacotherapy Specialist
    Board of Pharmacy Specialties

Research Profile

Research Interests: HIV/AIDS, microbiology, rapid diagnostics, novel agents for multidrug resistant infections, antimicrobial stewardship

Open Researcher and Contributor ID (ORCID)

0000-0001-5239-8303

Publications

2022
Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics.
Antimicrobial agents and chemotherapy. 66(2) [DOI] 10.1128/AAC.02046-21. [PMID] 34902271.
2022
Impact of Empiric Linezolid for Necrotizing Soft Tissue Infections on Duration of Methicillin-Resistant Staphylococcus aureus-Active Therapy.
Surgical infections. 23(3):313-317 [DOI] 10.1089/sur.2021.329. [PMID] 35133888.
2022
Implementation of a β-lactam therapeutic drug monitoring program: Experience from a large academic medical center.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 79(18):1586-1591 [DOI] 10.1093/ajhp/zxac171. [PMID] 35704702.
2022
Pharmacy student self-assessment of strength of residency candidacy compared to clinical faculty.
Currents in pharmacy teaching & learning. 14(3):304-309 [DOI] 10.1016/j.cptl.2022.01.017. [PMID] 35307089.
2022
Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
Antimicrobial Stewardship & Healthcare Epidemiology. 2(1) [DOI] 10.1017/ash.2022.21.
2021
Impact of supplemental individual verbal defense on confidence, engagement, and performance in a team-based learning therapeutics course.
Currents in pharmacy teaching & learning. 13(2):152-158 [DOI] 10.1016/j.cptl.2020.09.010. [PMID] 33454072.
2021
Implementation of a comprehensive intervention focused on hospitalized patients with HIV by an existing stewardship program: successes and lessons learned.
Therapeutic advances in infectious disease. 8 [DOI] 10.1177/20499361211010590. [PMID] 33953916.
2020
Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
The Annals of pharmacotherapy. 54(12):1252-1259 [DOI] 10.1177/1060028020933772. [PMID] 32517480.
2018
Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
International journal of antimicrobial agents. 51(4):629-635 [DOI] 10.1016/j.ijantimicag.2018.01.016. [PMID] 29408227.
2018
In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates.
Open forum infectious diseases. 5(7) [DOI] 10.1093/ofid/ofy158. [PMID] 30046642.
2015
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
The Annals of pharmacotherapy. 49(5):566-81 [DOI] 10.1177/1060028015570729. [PMID] 25680759.

Grants

Jun 2021 ACTIVE
A retrospective chart review study of cefiderocol real world outcomes and safety in the treatment of patients with Gram-negative bacterial infections (GNBI) in the US and Europe
Role: Principal Investigator
Funding: SHIONOGI INC
May 2021 ACTIVE
Prevalence of Cefazolin Inoculum Effect in Mcthicillin Susceptible Staphylococcus aureus Bacteremia
Role: Co-Project Director/Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL

Education

Pharm.D.
2015 · Degreem Wingate University School of Pharmacy

Contact Details

Phones:
Business:
(352) 594-5892
Emails:
Addresses:
Business Mailing:
PO Box 100486
GAINESVILLE FL 32610
Business Street:
PO Box 100486
GAINESVILLE FL 32610